What question did this study set out to answer?

To examine the role of EGFRvIII mutations in immunotherapy resistance and determine whether targeting adenosine improves therapeutic response in microsatellite stable colorectal cancer.

February 1, 2025Journal for ImmunoTherapy of CancerOpen Access

Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation

View Full Paper

Ask AI

Bookmark

Authors

FSFei SunUniversity of California, Los Angeles FYFangzhen YaoNanfang Hospital CZChunting ZengGuilin Medical University

Discussion

Member takes

Implication

Translational study demonstrates improved anti-PD-1 response via adenosine inhibition in EGFRvIII-mutated colorectal cancer, indicating a viable strategy against immunotherapy resistance.

Key Points

To examine the role of EGFRvIII mutations in immunotherapy resistance and determine whether targeting adenosine improves therapeutic response in microsatellite stable colorectal cancer.
Assessed circulating tumor cells and tumor tissues from multicenter cohorts of patients with colorectal cancer treated with cetuximab to evaluate EGFRvIII expression and immune cell infiltration.
Tested combination regimens of adenosine inhibitors and anti-PD-1 in syngeneic mouse models of EGFRvIII-mutated colorectal cancer.
EGFRvIII mutations occurred in approximately 10% of microsatellite stable colorectal cancers and correlated with poor response to cetuximab.
EGFRvIII-positive tumors established an adenosine-driven immunosuppressive tumor microenvironment.
Adenosine inhibition remodeled the tumor microenvironment, overcoming cetuximab resistance and markedly improving anti-PD-1 therapeutic efficacy.

Cite This Study

Sun et al. (2025) studied this question.

synapsesocial.com/papers/6a7fa40837804d00d37851cb https://doi.org/10.1136/jitc-2024-010126

View Full Paper

Ask AI

Bookmark

Implication

Translational study demonstrates improved anti-PD-1 response via adenosine inhibition in EGFRvIII-mutated colorectal cancer, indicating a viable strategy against immunotherapy resistance.

Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation

Discussion

Member takes

Implication

Key Points

Cite This Study

Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider